Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | GSK4381562 |
| Trade Name | |
| Synonyms | GSK-4381562|GSK 4381562|SRF813|SRF-813|SRF 813|Remzistotug |
| Drug Descriptions |
GSK4381562 (SRF813) is a monoclonal antibody targeting CD112R (PVRIG), which potentially increases NK cell activation and inhibits tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 4548). |
| DrugClasses | PVRIG Antibody 5 |
| CAS Registry Number | 2920425-39-2 |
| NCIT ID | C187105 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Dostarlimab-gxly + EOS-448 + GSK4381562 | Dostarlimab-gxly EOS-448 GSK4381562 | 0 | 1 |
| Dostarlimab-gxly + GSK4381562 | Dostarlimab-gxly GSK4381562 | 0 | 1 |
| GSK4381562 | GSK4381562 | 0 | 1 |